A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
NCT07918846, Phase 3, Not yet recruiting, Hoffmann-La Roche
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | ClinicalTrials.gov |
| NCT number | NCT07918846 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 8,200 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Hoffmann-La Roche | ClinicalTrials.gov |
| Conditions | Overweight, Obesity, Cardiovascular Disease | ClinicalTrials.gov |
| Interventions | Enicepatide, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 40
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Time to First Occurrence of Any Component of 5-point (5P) MACE | From randomization up to 4.2 years | The components of this composite 5P MACE endpoint consist of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for heart failure (HHF) or urgent heart failure (HF) visit, or urgent coronary revascularization. | ClinicalTrials.gov |
| Secondary | Time to First Occurrence of Any Component of 3-point (3P) MACE | From randomization up to 4.2 years | The components of this composite 3P MACE endpoint consist of CV death, non-fatal MI or non-fatal stroke. | ClinicalTrials.gov |
| Secondary | Time to New-Onset T2DM | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Total Occurrence of All-Cause Hospitalization | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Time to Death From Any Cause | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Time to CV Death | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Incidence and Severity of Adverse Events | From baseline up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Time to First Occurrence of Any Component of 4-point (4P) MACE | From randomization up to 4.2 years | The components of this composite 4P MACE endpoint consist of CV death, non-fatal MI, non-fatal stroke, or HHF or urgent HF visit. | ClinicalTrials.gov |
| Secondary | Time to First Occurrence of HHF, Urgent HF Visit, or CV Death | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Time to First Occurrence of HHF, Urgent HF Visit, or All-Cause Mortality | From randomization up to 4.2 years | ClinicalTrials.gov | |
| Secondary | Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the Short Form 36 Health Survey Version 2.0 (SF-36 V2) Acute Form Physical Functioning Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Physical Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Bodily Pain Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form General Health Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Vitality Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Social Functioning Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Emotional Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Health Domain Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Physical Component Summary Score | From baseline through Week 48 | ClinicalTrials.gov | |
| Secondary | Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Component Summary Score | From baseline through Week 48 | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)